307 related articles for article (PubMed ID: 8053973)
1. Bioavailability of iron from oral ferric polymaltose in humans.
Nielsen P; Gabbe EE; Fischer R; Heinrich HC
Arzneimittelforschung; 1994 Jun; 44(6):743-8. PubMed ID: 8053973
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations.
Kaltwasser JP; Werner E; Niechzial M
Arzneimittelforschung; 1987 Jan; 37(1A):122-9. PubMed ID: 3566867
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of trivalent iron in oral iron preparations. Therapeutic efficacy and iron absorption from simple ferric compounds and high- or low-molecular weight ferric hydroxide-carbohydrate complexes.
Heinrich HC
Arzneimittelforschung; 1975 Mar; 25(3):420-6. PubMed ID: 1174047
[TBL] [Abstract][Full Text] [Related]
4. Intestinal absorption of 59Fe from neutron-activated commercial oral iron(III)-citrate and iron(III)-hydroxide-polymaltose complexes in man.
Heinrich HC
Arzneimittelforschung; 1987 Jan; 37(1A):105-7. PubMed ID: 3566863
[TBL] [Abstract][Full Text] [Related]
5. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose.
Jacobs P; Johnson G; Wood L
J Med; 1984; 15(5-6):367-77. PubMed ID: 6599114
[TBL] [Abstract][Full Text] [Related]
6. Are ferric compounds useful in treatment of iron deficiency anemia?
Arvas A; Gür E
Turk J Pediatr; 2000; 42(4):352-3. PubMed ID: 11196760
[TBL] [Abstract][Full Text] [Related]
7. Iron hydroxide polymaltose: iatrogenic cause of persistent iron deficiency anaemia despite continuous oral iron therapy.
Mehta BC
J Assoc Physicians India; 2002 Feb; 50():279-80. PubMed ID: 12038667
[No Abstract] [Full Text] [Related]
8. On the therapeutic effects of trivalent and divalent iron in iron deficiency anaemia.
Sas G; Nemesanszky E; Bräuer H; Scheffer K
Arzneimittelforschung; 1984; 34(11):1575-9. PubMed ID: 6543133
[TBL] [Abstract][Full Text] [Related]
9. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A
Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600
[TBL] [Abstract][Full Text] [Related]
10. Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats.
Geisser P; Müller A
Arzneimittelforschung; 1984; 34(11):1560-9. PubMed ID: 6543131
[TBL] [Abstract][Full Text] [Related]
11. [Bioavailability of iron in oral iron preparations. Principles of duration and dosage (author's transl)].
Heinrich HC; Gabbe EE
MMW Munch Med Wochenschr; 1979 Aug; 121(35):1104-8. PubMed ID: 114773
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability and the mechanisms of intestinal absorption of iron from ferrous ascorbate and ferric polymaltose in experimental animals.
Johnson G; Jacobs P
Exp Hematol; 1990 Nov; 18(10):1064-9. PubMed ID: 2209759
[TBL] [Abstract][Full Text] [Related]
13. Effects of iron(II) salts and iron(III) complexes on trace element status in children with iron-deficiency anemia.
Sözmen EY; Kavakli K; Cetinkaya B; Akçay YD; Yilmaz D; Aydinok Y
Biol Trace Elem Res; 2003 Jul; 94(1):79-86. PubMed ID: 12907830
[TBL] [Abstract][Full Text] [Related]
14. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
15. Ferrous sulfate versus iron polymaltose complex for treatment of iron deficiency anemia in children.
Bopche AV; Dwivedi R; Mishra R; Patel GS
Indian Pediatr; 2009 Oct; 46(10):883-5. PubMed ID: 19430060
[TBL] [Abstract][Full Text] [Related]
16. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease.
Erichsen K; Ulvik RJ; Grimstad T; Berstad A; Berge RK; Hausken T
Aliment Pharmacol Ther; 2005 Nov; 22(9):831-8. PubMed ID: 16225492
[TBL] [Abstract][Full Text] [Related]
17. Iron(III)-hydroxide polymaltose complex in iron deficiency anemia / review and meta-analysis.
Toblli JE; Brignoli R
Arzneimittelforschung; 2007; 57(6A):431-8. PubMed ID: 17691593
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study.
Lindgren S; Wikman O; Befrits R; Blom H; Eriksson A; Grännö C; Ung KA; Hjortswang H; Lindgren A; Unge P
Scand J Gastroenterol; 2009; 44(7):838-45. PubMed ID: 19330567
[TBL] [Abstract][Full Text] [Related]
19. Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.
Hershko C; Ianculovich M; Souroujon M
Acta Haematol; 2007; 118(1):19-26. PubMed ID: 17426393
[TBL] [Abstract][Full Text] [Related]
20. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
